IP Library Patent Application 16253026
Patent Application
App. No. 16/253,026

BIOACTIVE GRAFTS AND COMPOSITES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/253,026
Abstract

Disclosed are various bioactive and/or biocompatible materials and methods of making the same.

Claims (31)

1 . An implant material comprising:

allograft bone obtained from a donor;

mesenchymal stem cells obtained from the donor, wherein the mesenchymal stem cells are attached to or are otherwise associated with the allograft bone; and

one or more non-recombinant intracellular growth factors obtained from lysed cells from the donor, wherein the one or more non-recombinant intracellular growth factors are attached to the allograft bone.

2 . The implant material of claim 1 , wherein at least one or more of the mesenchymal stem cells are viable.

3 . The implant material of claim 1 , wherein the one or more non-recombinant intracellular growth factors are selected from the group consisting of: a bone morphogenetic protein, a transforming growth factor beta, a growth differentiation factor, a cartilage derived morphogenetic protein, an interleukin, an interferon, a lymphokine, a chemokine, a platelet derived growth factor, a vascular endothelial growth factor, a fibroblast growth factor, and combinations thereof.

4 . The implant material of claim 1 , wherein the one or more non-recombinant intracellular growth factors is a bone morphogenetic protein (BMP).

5 . The implant material of claim 4 , wherein the BMP is selected from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, and combinations thereof.

7 . The implant material of claim 1 , wherein the allograft bone is allograft cortical bone.

8 . The implant material of claim 7 , wherein the allograft cortical bone is demineralized allograft cortical bone.

9 . The implant material of claim 8 , wherein the lysed cells are obtained from allograft cancellous bone from the donor, wherein the allograft cancellous bone comprises bone marrow.

10 . The implant material of claim 7 , wherein the lysed cells are obtained from allograft cancellous bone from the donor, wherein the allograft cancellous bone comprises bone marrow.

11 . The implant material of claim 1 , wherein the lysed cells are obtained from allograft cancellous bone from the donor, wherein the allograft cancellous bone comprises bone marrow.

12 . A method of making an implant material, the method comprising:

(a) selectively lysing allograft cancellous bone obtained from a donor, wherein the cancellous allograft bone comprises bone marrow, wherein selective lysing comprises exposing allograft cancellous bone obtained from a donor to a lysing fluid to selectively lyse non-mesenchymal stem cells while not lysing mesenchymal stem cells contained in the allograft cancellous bone, wherein the lysing fluid is water or less than 1M acetic acid,

wherein the intracellular growth factors contained in the lysed non-mesenchymal stem cells are released into the lysing fluid, and

wherein the lysing fluid after lysing comprises mesenchymal stem cells and intracellular growth factors released from non-mesenchymal stem cells; and

(b) mixing the lysing fluid obtained from step (a) that comprises mesenchymal stem cells an released intracellular growth factors with allograft cortical bone,

wherein at least one of the mesenchymal stem cells attach or otherwise associate with the allograft cortical bone, and

wherein at least one of the released intracellular growth factors bind or otherwise associate with the allograft cortical bone.

13 . The method of claim 12 , wherein the one or more intracellular growth factors are selected from the group consisting of: a bone morphogenetic protein, a transforming growth factor beta, a growth differentiation factor, a cartilage derived morphogenetic protein, an interleukin, an interferon, a lymphokine, a chemokine, a platelet derived growth factor, a vascular endothelial growth factor, a fibroblast growth factor, and combinations thereof.

14 . The method of claim 13 , wherein the one or more non-recombinant intracellular growth factors is a bone morphogenetic protein (BMP).

15 . The method of claim 14 , wherein the BMP is selected from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, and combinations thereof.

16 . The method of claim 12 , wherein one or more of the mesenchymal stem cells are viable.

17 . The method of claim 12 , wherein the allograft cortical bone is demineralized before mixing with the lysing fluid obtained in step (a).

18 . A method comprising:

administering an implant to a subject in need thereof, wherein the implant comprises allograft cortical bone obtained from a donor;

mesenchymal stem cells obtained from the donor, wherein the mesenchymal stem cells are attached to or are otherwise associated with the allograft cortical bone; and

one or more non-recombinant intracellular growth factors obtained from lysed cells from the donor, wherein the one or more non-recombinant intracellular growth factors are attached to the allograft cortical bone, wherein the lysed cells were obtained from allograft cancellous bone comprising bone marrow.

19 . The method of claim 18 , wherein the allograft cortical bone is demineralized.

20 . The method of claim 18 , wherein one or more of the mesenchymal stem cells is viable.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2025
From: BARINGS FINANCE LLC, AS COLLATERAL AGENT
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
Reel/Frame 072274/0408 →
SECURITY INTEREST Recorded Oct 18, 2023
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
To: BARINGS FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065271/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2020
From: GOVIL, AMIT PRAKASH; GAMBOA, CHRISTIAN
To: BIOVENTUS, LLC
Reel/Frame 051432/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2020
From: BIOVENTUS, LLC
To: ADVANCED BIOLOGICS, LLC
Reel/Frame 051436/0462 →